leuprolide acetate for depot suspension / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 138 Diseases   93 Trials   93 Trials   2194 News 


«12...1213141516171819202122...3334»
  • ||||||||||  leuprorelin depot / Generic mfg.
    Preclinical, Journal:  Daily GnRH agonist treatment delays the development of reproductive physiology and behavior in male rats. (Pubmed Central) -  Nov 4, 2021   
    By the last test, the leuprolide-treated subjects showed signs of catching up, however, many continued to be delayed. Estradiol and progesterone mildly feminized male physiology (e.g., decreased testes weight and serum testosterone) and behavior (e.g., increased lordosis), but did not interact with leuprolide treatment.
  • ||||||||||  leuprorelin depot / Generic mfg.
    Journal:  Leuprolide acetate (Fensolvi) for central precocious puberty. (Pubmed Central) -  Oct 28, 2021   
    The changes of ovarian volume and the major axes of the ovary, uterus, cervix can be used as sensitive observation indexes. No abstract available
  • ||||||||||  leuprorelin depot / Generic mfg.
    Journal:  Effects of Estradiol on Immunoglobulin G Glycosylation: Mapping of the Downstream Signaling Mechanism. (Pubmed Central) -  Oct 27, 2021   
    Aiming to investigate the effect of estrogen on IgG glycosylation, we analysed IgG and total serum glycomes in 36 healthy premenopausal women enrolled in a randomized controlled trial of the gonadotropin-releasing hormone analogue (GnRH) leuprolide acetate to lower gonadal steroids to postmenopausal levels and then randomized to transdermal placebo or estradiol (E) patch...To determine whether previously identified IgG GWAS hits RUNX1, RUNX3, SPINK4, and ELL2 are involved in downstream signaling mechanisms, linking E with IgG glycosylation, we used the FreeStyle 293-F transient system expressing IgG antibodies with stably integrated CRISPR/dCas9 expression cassettes for gene up- and downregulation. RUNX3 and SPINK4 upregulation using dCas9-VPR resulted in a decreased IgG galactosylation and, in the case of RUNX3, a concomitant increase in IgG agalactosylation.
  • ||||||||||  progesterone / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
    Trial completion date, Trial primary completion date:  Metabolic Study of Women With Polycystic Ovary Syndrome and Sleep Apnea (clinicaltrials.gov) -  Oct 18, 2021   
    P=N/A,  N=80, Active, not recruiting, 
    Trial completion date: Jan 2023 --> Jul 2023 Trial completion date: Jan 2021 --> Jun 2023 | Trial primary completion date: Jan 2021 --> Jun 2022
  • ||||||||||  leuprorelin depot / Generic mfg., abiraterone acetate / Generic mfg.
    [VIRTUAL] A RARE CASE OF MALIGNANT PLEURAL EFFUSION DUE TO PROSTATE CANCER () -  Oct 13, 2021 - Abstract #CHEST2021CHEST_2201;    
    This patient developed an isolated left-sided effusion as the presenting feature of disease progression while on treatment with leuprolide and abiraterone. While rare, symptomatic malignant effusions from prostate cancer can present at any time during a patient's disease course and can be managed similar to other malignant pleural effusions.
  • ||||||||||  leuprorelin depot / Generic mfg.
    [VIRTUAL] ENDOBRONCHIAL METASTASIS FROM PROSTATE CANCER PRESENTING AS A "NONRESOLVING PNEUMONIA" AND RESPONDING TO HORMONAL THERAPY () -  Oct 13, 2021 - Abstract #CHEST2021CHEST_975;    
    Endobronchial metastases from unusual primaries, such as prostrate, can present as a post-obstructive, non-resolving pneumonia more than 4 years from the primary diagnosis. The clinician should have a high index of suspicion for this rare presentation when evaluating a non-resolving pneumonia in a patient with a history of malignancy including that due to prostate cancer, for which endobronchial evaluation and hormonal treatment may be indicated.
  • ||||||||||  leuprorelin depot / Generic mfg.
    [VIRTUAL] FROM THE PROSTATE TO THE LUNGS WITHOUT ANY BONY STOPOVERS () -  Oct 13, 2021 - Abstract #CHEST2021CHEST_958;    
    This case emphasizes the importance of considering prostate cancer in the differential diagnosis of male patients presenting with pulmonary nodules, even in the absence of bony metastasis. It also demonstrates the importance of immunohistochemistry in identifying the site of origin for cancer lesions.
  • ||||||||||  leuprorelin depot / Generic mfg.
    [VIRTUAL] AGGRESSIVE CASE OF BENIGN METASTATIC LEIOMYOMA LEADING TO PATIENT'S DEMISE () -  Oct 13, 2021 - Abstract #CHEST2021CHEST_932;    
    BML can progress many years after hysterectomy and after initial diagnosis despite estrogen reducing medications. BML most common organ of metastases is the lungs, and despite the benign histology, it can lead to significant morbidity and mortality due to compression of vital organs including the airways and heart.
  • ||||||||||  Xtandi (enzalutamide capsule) / Pfizer, Astellas
    Trial termination:  Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer (clinicaltrials.gov) -  Oct 12, 2021   
    P2,  N=11, Terminated, 
    BML most common organ of metastases is the lungs, and despite the benign histology, it can lead to significant morbidity and mortality due to compression of vital organs including the airways and heart. Completed --> Terminated; Low Accrual
  • ||||||||||  leuprorelin depot / Generic mfg.
    Clinical, Journal:  Concordance between prostate biopsy and radical prostatectomy specimen Gleason score at the Carlos Andrade Marín hospital between January 2016 and December 2018. (Pubmed Central) -  Oct 5, 2021   
    The agreement of the prostate biopsy in relation to the surgical piece of radical prostatectomy is in the context of that reported in international studies, over staging does not represent a major health problem since patients could benefit from the radical prostatectomy but under-Staging could lead to the decision not to provide the patient a curative treatment of his disease tobe referred to an active surveillance protocol. Vanishing prostate cancer in this study group is explained by the use of hormonal blockade with leuprolideacetate prior to surgical treatment in two patients and a low tumor invasion in the histopathology sample of the third patient.
  • ||||||||||  Enrollment open:  STAMP: Strength, Aging, and Memory in Prostate Cancer (clinicaltrials.gov) -  Oct 3, 2021   
    P=N/A,  N=60, Recruiting, 
    Vanishing prostate cancer in this study group is explained by the use of hormonal blockade with leuprolideacetate prior to surgical treatment in two patients and a low tumor invasion in the histopathology sample of the third patient. Not yet recruiting --> Recruiting
  • ||||||||||  leuprorelin depot / Generic mfg., tamoxifen / Generic mfg.
    Clinical, Review, Journal:  Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women. (Pubmed Central) -  Oct 2, 2021   
    Consequently, for many years, tamoxifen monotherapy has been the standard of care for endocrine treatment in the adjuvant setting...Luteinizing hormone-releasing hormone agonists (LHRHa), including goserelin, triptorelin, and leuprorelin, achieve OFS through sustained suppression of the release of follicle-stimulating hormone and luteinizing hormone from the pituitary...We also discuss the role of LHRHa use in combination with adjuvant chemotherapy to preserve ovarian function and fertility in young patients with breast cancer. Finally, we discuss important practical aspects of the use of LHRHa in breast cancer treatment, including side-effects, patient adherence to treatment, and the use of slow-release, long-acting drug formulations.
  • ||||||||||  leuprorelin depot / Generic mfg., spironolactone / Generic mfg.
    Clinical, Review, Journal:  A systematic review of anti-androgens and feminisation in transgender women. (Pubmed Central) -  Oct 1, 2021   
    However, due to spironolactone's antagonism of the androgen receptor, it is unclear whether this results in clinically meaningful differences in feminisation. Further research with clinically meaningful endpoints is needed to optimise the use of anti-androgens in transgender women.
  • ||||||||||  leuprorelin depot / Generic mfg.
    Journal:  Which parameters predict the beneficial effect of GnRHa treatment on height in girls with central precocious puberty? (Pubmed Central) -  Oct 1, 2021   
    Further research with clinically meaningful endpoints is needed to optimise the use of anti-androgens in transgender women. Treatment with GnRHa is unquestionably beneficial to improve FH in girls with iCPP when initiated ≤6.4 years of age.GnRHa treatment after 8.3 years of age may not improve FH.Girls between the ages of 6.4-8.3 years at presentation can have a better height gain if BA (≥2.6 years over CA) and pubertal findings (pubertal stage≥3, or E ≥32.6pg/ml) are well-advanced.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  CCRO025: Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate (clinicaltrials.gov) -  Sep 28, 2021   
    P=N/A,  N=29, Recruiting, 
    Even though, some characteristics of the disease, such as increased weight and body fat, negatively influence the telomere biology. Trial completion date: Nov 2021 --> Nov 2022 | Trial primary completion date: May 2021 --> May 2022
  • ||||||||||  leuprorelin depot / Generic mfg.
    Preclinical, Journal:  Effect of Polymer Source on In Vitro Drug Release from PLGA Microspheres. (Pubmed Central) -  Sep 24, 2021   
    Accordingly, the objectives of the present research were: 1) to determine minor differences in the physicochemical properties (such as inherent viscosity/molecular weight (Mw), blockiness, and glass transition temperature (Tg)) and the hydrolytic degradation profiles of PLGA polymers from different sources; and 2) to investigate the impact of any differences determined in (1) on the physicochemical properties (Q3) and in vitro release of leuprolide acetate microspheres...These results indicate that polymer source related variations have the potential to significantly impact the Q3 sameness and therapeutic performance of long-acting PLGA microspheres. The fundamental understanding gained on polymer properties will make a critical contribution to the development of quality control strategies as well as to future regulatory guidance on the evaluation of such complex drug products.
  • ||||||||||  sunitinib / Generic mfg.
    Trial completion date, Trial primary completion date:  Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy (clinicaltrials.gov) -  Sep 23, 2021   
    P2,  N=64, Active, not recruiting, 
    The fundamental understanding gained on polymer properties will make a critical contribution to the development of quality control strategies as well as to future regulatory guidance on the evaluation of such complex drug products. Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2021